Chronic exposure to low doses of pharmaceuticals disturbs the hepatic expression of circadian genes in lean and obese mice.

Sébastien Anthérieu, Dounia Le Guillou, Cédric Coulouarn, Karima Begriche, Viviane Trak-Smayra, Sophie Martinais, Mathieu Porceddu, Marie-Anne Robin, Bernard Fromenty

► To cite this version:

Sébastien Anthérieu, Dounia Le Guillou, Cédric Coulouarn, Karima Begriche, Viviane Trak-Smayra, et al.. Chronic exposure to low doses of pharmaceuticals disturbs the hepatic expression of circadian genes in lean and obese mice.. *Toxicology and Applied Pharmacology*, 2014, 276 (1), pp.63-72. 10.1016/j.taap.2014.01.019 . hal-01057872

HAL Id: hal-01057872

<https://hal-univ-rennes1.archives-ouvertes.fr/hal-01057872>

Submitted on 25 Aug 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Chronic exposure to low doses of pharmaceuticals disturbs the hepatic expression of circadian genes in lean and obese mice

Sébastien Anthérieu^{a, †}, Dounia Le Guillou^{a, †}, Cédric Coulouarn^a, Karima Begriche^a, Viviane Trak-Smayra^b, Sophie Martinais^a, Mathieu Porceddu^c, Marie-Anne Robin^a, Bernard Fromenty^{a,*}

^aINSERM, U991, Université de Rennes 1, 35000 Rennes, France

^bPathology Department, Saint-Joseph University, Beirut, Lebanon

^cMitologics SAS, Hôpital Robert Debré, 48 boulevard Sérurier, 75019 Paris, France

*Corresponding author at: INSERM, U991, Université de Rennes 1, 35000 Rennes, France.

E-mail address: bernard.fromenty@inserm.fr

[†]These authors contributed equally to this work

Abbreviations: Alas1, aminolevulinic acid synthase 1; ALT, alanine aminotransferase; APAP, acetaminophen; Arntl, aryl hydrocarbon receptor nuclear translocator-like; Arrdc3, arrestin domain containing 3; AST, aspartate aminotransferase; Atp2b2, ATPase calcium transporting, plasma membrane 2; Bmal1; brain and muscle ARNT-like 1; Clock, circadian locomotor output cycles kaput; Cry1, Cryptochrome 1; CYP, cytochromes P450; Dbp, D site albumin promoter binding protein; GEO, gene expression omnibus; GSEA, gene set enrichment analysis; H&E, hematoxylin-eosin; Mt, metallothionein; Npas2, neuronal PAS domain protein 2; Per, period circadian clock; RT-qPCR, Real-time quantitative PCR; Usp2, ubiquitin specific peptidase 2.

ABSTRACT

Drinking water can be contaminated with pharmaceuticals. However, it is uncertain whether this contamination can be harmful for the liver, especially during obesity. Hence, the goal of our study was to determine whether chronic exposure to low doses of pharmaceuticals could have deleterious effects in livers of lean and obese mice. To this end, lean and ob/ob male mice were treated for 4 months with a mixture of 11 drugs provided in drinking water at concentrations ranging from 10 to 10^6 ng/l. At the end of the treatment, some liver and plasma abnormalities were observed in ob/ob mice treated with the cocktail containing 10^6 ng/l of each drug. For this dosage, a gene expression analysis by microarray showed altered expression of circadian genes (e.g. Bmal1, Dbp, Cry1) in lean and obese mice. RT-qPCR analyses carried out in all groups of animals confirmed that expression of 8 different circadian genes was modified in a dose-dependent manner. For some genes, a significant modification was observed for dosages as low as 10^2 - 10^3 ng/l. Drug mixture and obesity presented an additive effect on circadian gene expression. These data were validated in an independent study performed in female mice. Thus, our study showed that chronic exposure to trace pharmaceuticals disturbed hepatic expression of circadian genes, particularly in obese mice. Because some of the 11 drugs can be found in drinking water at such concentrations (e.g. acetaminophen, carbamazepine, ibuprofen) our data could be relevant in environmental toxicology, especially for obese individuals exposed to these contaminants.

Key words: microarray; drug; liver; mouse; obesity; circadian rhythm

69 Introduction

70

71 Contamination of air, soil and water with pharmaceuticals and personal care products is currently
72 a major concern for many countries. Indeed, such contamination could endanger the health of
73 millions of individuals, especially in the case of chronic and multiple exposures in sensitive
74 populations (Sanderson, 2011). Regarding pharmaceuticals, it is noteworthy that the parent drugs
75 and their metabolites are excreted by patients as waste and some people also get rid of unused
76 pharmaceuticals in the toilets. Hence, all these pharmaceuticals can thereafter be found in water
77 (Kasprzyk-Hordern et al., 2008; Mompelat et al., 2009). For instance, the following drugs were
78 detected in tap water in several independent studies: acetaminophen (APAP), bezafibrate and other
79 fibrates, caffeine, carbamazepine, cotinine (a nicotine metabolite), diazepam, diclofenac,
80 erythromycin, flumequine, ibuprofen, phenazone (antipyrine), roxithromycin, salicylic acid and
81 sulfamethoxazole (Daughton and Ternes, 1999; Halling-Sorensen et al., 1998; Heberer, 2002;
82 Mompelat et al., 2009; Stackelberg et al., 2004; Webb et al., 2003; Ye and Weinberg, 2007; Yu et
83 al., 2007; Zuccato et al., 2000). As reported in most of these investigations, these drugs were found
84 in the drinking water at concentrations ranging generally between 1 and 20 ng/l. However, for some
85 pharmaceuticals such as APAP, caffeine, carbamazepine, fibrates, ibuprofen and phenazone, several
86 hundreds of ng/l were sometimes found in tap water (Daughton and Ternes, 1999; Mompelat et al.,
87 2009).

88 Long-term exposure to drug contaminants could have deleterious consequence for some
89 sensitive tissues, especially the liver. Indeed, liver expresses high levels of cytochromes P450
90 (CYPs) that can transform drugs into toxic metabolites, which are able to induce oxidative stress,
91 mitochondrial dysfunction and cell death (Aubert et al., 2012; Leung et al., 2012). It is also worthy
92 to mention that recent investigations indicated that the liver could be particularly sensitive to drug-
93 induced toxicity in the context of obesity (Aubert et al., 2012; Fromenty, 2013).

94 Taken all these data into consideration, the aim of the present study was to determine the long-
95 term hepatic effects of pharmaceutical contaminants in lean and obese ob/ob mice. These mice were
96 treated for 4 months with a mixture of 11 drugs provided in drinking water at concentrations ranging
97 from 10 to 10^6 ng/l. These drugs included APAP, caffeine, carbamazepine, cotinine, diclofenac,
98 erythromycin, ibuprofen, phenazone, roxithromycin, salicylic acid and sulfamethoxazole.
99 Importantly, all these molecules were previously detected in drinking water, as mentioned
100 previously.

101 **Materials and methods**

102

103 *Animals and exposure to drugs.* Five-week-old male C57BL/6J-+/+ mice (wild-type, also referred to
104 as lean mice) weighing 19 to 20g and C57BL/6J-ob/ob mice, weighing 28 to 32 g, were purchased
105 from Janvier (Le-Genest-St-Isle, France) and housed in the animal house facility of Rennes 1
106 University under a 12 h light-dark cycle. All mice were fed ad libitum on a normal diet bringing 2820
107 kcal per kg of food (A04 biscuits; UAR, Villemoisson-sur-Orge, France). After 1 week of
108 acclimatization, wild-type and ob/ob mice were further split into 7 different groups that were treated
109 or not with a drug cocktail containing 11 molecules at the following concentrations: 10, 10², 10³,
110 10⁴, 10⁵ and 10⁶ ng/l. All these drugs (APAP, caffeine, carbamazepine, cotinine, diclofenac,
111 erythromycin, ibuprofen, phenazone, roxithromycin, salicylic acid and sulfamethoxazole) were
112 purchased from Sigma-Aldrich (St. Quentin-Fallavier, France). Considering the molecular weight of
113 the molecules, 10⁶ ng/l corresponded to concentrations ranging from 1.2 µM for roxithromycin to
114 7.2 µM for salicylic acid. In a second independent series of investigations, five-week-old female
115 C57BL/6J-+/+ and C57BL/6J-ob/ob mice were purchased from Janvier (Le-Genest-St-Isle, France)
116 and housed in the animal house facility of the Robert Debré Hospital. In this study, mice were
117 treated or not with the same cocktail containing the 11 drugs at the following concentrations: 10⁴,
118 10⁵ and 10⁶ ng/l. For both studies conducted in Rennes and Paris, mice were exposed during 4
119 months to these drugs by way of the drinking water, which was renewed every week. Because ob/ob
120 mice are drinking more than lean mice (Fromenty et al. 2009; Massart et al. 2012), drug
121 concentrations in the drinking water was adapted in the group of obese mice to keep constant the
122 daily intake of the drugs between lean and obese mice. Consumption of water was monitored every
123 week and it was not reduced by the presence of the mixture, whatever the drug concentrations. The
124 last day of the treatment, blood was drawn in the morning between 10 a.m. and 2 p.m. Blood
125 withdrawal was carried out from the retro orbital sinus with heparinized capillary Pasteur pipettes
126 for biochemistry analyses. Mice were then sacrificed by cervical dislocation and liver was quickly
127 removed. While a majority of the liver fragments were immediately frozen in liquid nitrogen some
128 of them were rapidly processed for appropriate histological staining. Collected tissues frozen in
129 liquid nitrogen were subsequently stored at -80°C until use. All experiments were performed
130 according to national guidelines for the use of animals in biomedical research and approved by the
131 local Ethics Committee in Animal Experiment of Rennes 1 University and Robert Debré Hospital.

132

133 *Plasma analyses.* Immediately after collection, blood was centrifuged for 10 min at 1000g and
134 plasma was stored at -20°C until assay. Plasma activity of alanine aminotransferase (ALT) and

135 aspartate aminotransferase (AST), total cholesterol, triglycerides and glucose levels were measured
136 on an automatic analyzer AU2700 (Olympus Diagnostics, Rungis, France) with Olympus
137 commercial Kits OSR6107, OSR6109, OSR6116, OSR6133 and OSR6121, respectively.

138

139 *Liver histology.* To evaluate necrosis, inflammation and steatosis, liver fragments were fixed in 10%
140 neutral formalin and embedded in paraffin. Then, 4- μ m thick sections were cut and stained with
141 hematoxylin-eosin (H&E). All these sections were thoroughly examined by an experienced
142 pathologist (V.T.-S.). The amount of hepatic steatosis in ob/ob and the classification of this lesion
143 into 3 different categories (i.e. microvesicular, mediovesicular and macrovacuolar) were determined
144 as recently described (Trak-Smayra et al., 2011).

145

146 *RNA extraction and gene expression profiling.* For the microarrays, total RNA extraction, linear T7-
147 based amplification step, hybridization procedure, detection and read out of the fluorescence signals
148 were carried out by Miltenyi Biotec GmbH (Bergisch Gladbach, Germany). Total RNA was
149 extracted from liver samples using a standard RNA extraction protocol (Trizol) and quality-checked
150 with an Agilent 2100 Bioanalyzer platform. All RNA samples revealed RNA Integrity Number
151 (RIN) values between 7.2 and 8. Further information on T7-based amplification, Cy3-labeling,
152 hybridization of the Agilent microarray and detection of the fluorescent signals is given in the
153 Supplementary Data.

154

155 *Analysis and data mining of microarray data.* Gene expression data were analyzed using Feature
156 Extraction and GeneSpring softwares (Agilent Technologies) and further analyzed using R-based
157 array tools, as previously described (Sulpice et al., 2013). Agilent Feature Extraction Software was
158 used to read out and process the microarray image files. This software determines feature intensities
159 (including background subtraction), rejects outliers and calculates statistical confidences. Features
160 that were not positive and significant or below the background signal were filtered out. Microarray
161 data were normalized by using the 75th percentile shift normalization algorithm. Differentially
162 expressed genes were identified by a two-sample univariate *t*-test and a random variance model as
163 previously described (Coulouarn et al., 2012). Clustering analysis was done using Cluster 3.0 and
164 TreeView 1.6 with uncentered correlation and average linkage options. Enrichment for specific
165 biological functions or canonical pathways was evaluated by using gene ontology annotations, as
166 described previously (Coulouarn et al., 2012). Gene set enrichment analysis (GSEA) was performed
167 using the Java-tool developed at the Broad Institute (Cambridge, MA, USA). Microarray data were
168 submitted to the gene expression omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo;
169 GSE49195).

170

171 *Real-time quantitative PCR (RT-qPCR) analysis.* In order to study the hepatic mRNA expression of
172 selected genes, cDNAs were prepared by reverse transcription of 1 µg of total RNA using the High
173 Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Courtaboeuf, France). cDNAs were
174 thus amplified with specific primers using the Power SYBRGreen PCR Master Mix (Applied
175 Biosystems), in an ABI Prism 7900 instrument (Applied Biosystems). Further information on PCR
176 analysis is provided in the Supplementary Data.

177

178 *Statistical analysis.* Data are presented as means ± SEM (standard error of mean). In order to assess
179 statistical significances for body weight, plasma parameters and hepatic mRNA expression of
180 selected genes, a two-way Analysis of variance (ANOVA) was performed with the factors of
181 genotype (G) and drug mixture treatment (T). Individual means were compared with the post hoc
182 Bonferroni test.

183

Results

Body weight, plasma parameters and liver histology

Body weight was measured on a regular basis for each mouse so that the gain of body weight could be calculated over the 4-month period of treatment. Body weight was 31.2 ± 1.0 and 60.6 ± 1.0 g, respectively in untreated lean and obese mice at the end of the treatment. The gain of body weight was higher in obese mice compared to lean mice and the treatment significantly modified this parameter (Table 1). However, it was either decreased, unchanged or increased depending in the different groups with no dose-dependent effect (Table 1).

Some plasma parameters were measured at the end of the treatment. When compared to lean mice, untreated ob/ob mice presented higher levels of plasma ALT, AST and total cholesterol but normal levels of plasma triglycerides (Table 1), as previously reported (Fromenty et al., 2009; Lindström, 2007; Massart et al., 2012). In addition, the obese mice did not present hyperglycemia (Table 1), which was consistent with previous data showing that the diabetic state of ob/ob mice ameliorated with age (Fromenty et al., 2009; Lindström, 2007). Interestingly, treatment with the drug mixtures significantly modified the plasma levels of total cholesterol and ALT (Table 1). This was particularly evident in ob/ob mice treated with the cocktail containing 10^6 ng/l of each drug since this group of animals presented the highest plasma levels of total cholesterol and ALT (Table 1).

Liver histology was also studied at the end of the treatment in mice treated or not with the cocktails containing 10^5 and 10^6 ng/l of each drug. There were no histological alterations in lean mice whatever the groups of animals (data not shown). Slight necroinflammation was observed in untreated obese mice (data not shown), which could explain higher levels of plasma AST and ALT (Begriche et al., 2008; Trak-Smayra et al., 2011). However, treatment with the drug mixture did not aggravate the histological score of necroinflammation (data not shown).

Hepatic steatosis was observed in all obese mice (Supplementary Table 1) but this lesion was absent in lean mice, treated or not with the cocktails (data not shown). Although the percentage of hepatocytes with steatosis was unchanged by the treatment in ob/ob mice, a lower proportion of microvesicular steatosis was observed in obese mice treated with the cocktail containing 10^6 ng/l of each drug (Supplementary Table 1). Accordingly, the fat droplets were larger in treated ob/ob mice when compared to the controls (Fig. 1).

Microarray analysis

Gene expression profiling was carried out in order to determine whether the cocktail containing 10^6 ng/l of each drug induced transcriptional changes in the livers of lean and obese mice. Unsupervised microarray analysis demonstrated that the cocktail significantly modified the hepatic expression of 280 and 284 genes ($P < 0.05$; fold-change > 1.5), respectively in lean and obese mice. Among these genes, only 21 were dysregulated in both genotypes thus suggesting that drug-induced transcriptional changes were tightly dependent of the genetic background. Table 2 provides the top 10 well-annotated genes that were up or down-regulated by the cocktail in lean and obese mice. Interestingly, when a gene ontology analysis was performed, circadian rhythm was found as the only functional category significantly enriched for the hepatic genes differentially expressed by the cocktail in both lean and obese mice (Supplementary Table 2). In addition, this analysis indicated that the functional categories were linked to biosynthetic processes and transcription factor activity in lean mice and to cell cycle and cytoskeleton for ob/ob mice (Supplementary Table 2). Although this was not the main goal of this study, our unsupervised microarray analysis allowed us to determine the differential hepatic gene expression between lean and ob/ob mice. Our analysis identified 2,434 non-redundant genes that were differentially expressed between lean and obese mice ($P < 0.001$; fold-change > 2 ; data not shown). As previously reported (Fromenty et al., 2009; Yang et al., 2010), ob/ob mice were characterized by an increased expression of many genes involved in lipid synthesis, such as Elov17 (x15.9), Scd2 (x12.7), Agpat9 (x8.3), Elov16 (x7.7), Gpam (x5.3), Fasn (x4.6), Acaca (x4.6), Acly (x4.2), Pparg (x4.0) and Thrsp (x3.1). Moreover, there was in ob/ob mice a profound up- or down-regulation of the hepatic expression of several genes involved in the circadian rhythm such as Dbp (x14.3), Per3 (x7.1), Clock (x0.49), Arntl (also referred to as Bmal1) (x0.42) and Cry1 (x0.28). Interestingly, a recent study carried out in ob/ob mice reported lower hepatic expression of the last three genes compared to wild-type mice when the animals were investigated at zeitgeber times similar to our investigations (i.e. zeitgeber times 2 to 6) (Ando et al., 2011). In order to validate the whole data set obtained from our microarray analysis, a GSEA was performed using independent hepatic gene expression profiles from ob/ob and lean mice (Sharma et al. 2010), uploaded from the GEO database (GSE20878). Importantly, GSEA demonstrated that up- and down-regulated genes in ob/ob livers identified in our study were significantly enriched in the respective gene profiles of ob/ob and lean mice from the independent GSE20878 dataset (Supplementary Fig. 1).

247

248 *mRNA expression of specific genes*

Some genes of interest were selected to determine by RT-qPCR their hepatic expression in mice treated or not with the cocktail containing the 11 drugs at concentrations ranging from 10 to 10^6 ng/l. Since the gene ontology analysis pointed a specific dysregulation of genes involved in the

252 circadian rhythm in lean and obese mice, the expression of Bmal1, Clock, Dbp, Npas2, Per1, Per2,
253 Per3, and Cry1 was studied in all groups of mice. As shown in Fig. 2, the drug cocktail presented a
254 significant effect on gene expression, which was either decreased (Bmal1, Clock, Npas2, Cry1) or
255 increased (Dbp, Per1, Per2, Per3). A clear dose-effect response was observed in lean and/or obese
256 mice for the expression of all these genes. Moreover, drug mixture and obesity presented an additive
257 effect on circadian gene expression. Importantly, the cocktail presented a significant effect on
258 Bmal1, Dbp, Npas2, Per2, Per3, and Cry1 expression when it contained as low as 10^2 and 10^3 ng/l
259 of each drug in the mixture (Fig. 2). For these concentrations, it could be estimated that each drug
260 was administered to mice at the respective doses of 20 and 200 ng/kg/d, when considering the daily
261 intake of water and the body weight of the animals.

262 Because our gene expression profiling was performed on male mice solely, we next validated
263 our results on female mice. To this end, an independent series of lean and ob/ob female mice was
264 treated or not for 4 months with mixtures containing 10^4 , 10^5 and 10^6 ng/l of each drug, as described
265 in the Methods section. Interestingly, the profiles of drug-induced modification of circadian liver
266 gene expression were about similar to those observed in male mice, except for Per1 (Fig. 3). It was
267 noteworthy, however, that the effect of obesity on the hepatic expression of these genes was less
268 pronounced in female mice (Fig. 3) when compared to males (Fig. 2). We also noticed that the liver
269 expression of the circadian genes was in general higher in female mice, especially in wild-type
270 animals (Supplementary Fig. 2), which was consistent with a recent study (Xu et al., 2012).

271 Finally, we determined the hepatic expression of several genes not directly related to circadian
272 rhythm such as Alas1, Arrdc3, Mt1, Mt2, Usp2 and Atp2b2, the expression of which was found
273 dysregulated in the microarray analysis performed in male mice treated with the highest doses of the
274 drugs (Table 2). Interestingly, a dose-effect response was in general observed for the expression of
275 these 6 genes (Fig. 4). However, in female mice, only the expression of Arrdc3 and Usp2 was found
276 to be comparable when compared to male mice (data not shown).

277

Discussion

This study showed for the first time that chronic oral exposure to low doses of pharmaceuticals disturbed the hepatic expression of genes involved in circadian rhythm in mice. These transcriptional effects were dose-dependent and particularly robust since they were found in lean and obese male mice but also in female animals of both genotypes. In male mice, and to a lesser extent in female mice, drug mixture and obesity presented an additive effect on the expression of circadian genes such as *Dbp*, *Per2* and *Per3*. Moreover, the expression of some circadian genes was dysregulated when the drinking water contained the 11 drugs at concentrations as low as 10^2 and 10^3 ng/l. Such exposure corresponded to a daily intake of about 20 to 200 ng/kg/d. Hence, our data indicated that a mixture of pharmaceutical contaminants can alter the expression of hepatic genes at concentrations that can be found in drinking water. Indeed, for some drugs such as APAP, caffeine, carbamazepine, ibuprofen and phenazone, several hundreds of ng/l were found in tap water in previous studies (Daughton and Ternes, 1999; Mompelat et al., 2009).

A “whole mixture approach” was used in this study, and thus our investigations were not designed to determine which drug(s) could be involved in these hepatic effects, in particular on the expression of circadian genes. Nevertheless, it is noteworthy that some drugs such as prednisolone (Koyanagi et al., 2006), 5-fluorouracil (Terazono et al., 2008), interferon- α (Shinohara et al., 2008) and caffeine (Oike et al., 2011; Sherman et al., 2011) can disturb in liver the expression of genes involved in circadian rhythm. However, apart from caffeine, no information was found in the literature regarding this issue for the other drugs contained in the mixture. Although caffeine could have induced the genomic effects reported in our study, it is noteworthy that studies reporting caffeine-induced altered hepatic expression of clock genes were performed with much higher doses (from 3.5 to ca. 75 mg/kg/d) (Oike et al., 2011; Sherman et al., 2011). Thus, further investigations by treating mice with each drug separately would be needed to determine which component(s) of the mixture could alter the liver expression of clock genes when administered at very low doses. However, it is possible that the deleterious effects of the mixture uncovered in the present study might have been less significant with each individual drug (or might not have been observed), as suggested by some investigations in other experimental models (Christiansen et al., 2009; Kortenkamp et al., 2007). Interestingly, some of the drugs included in the cocktails belong to the same pharmacological classes (mainly nonsteroidal anti-inflammatory drugs and antibiotics). Therefore, it would be worth finding out whether the genomic effects detected in this study could be attributed to a particular drug class.

311 Although the expression of hepatic genes was disturbed in mice treated for 4 months with the
312 cocktails containing 10^2 and 10^3 ng/l of each drug, these concentrations did not change the plasma
313 parameters assessed in this study, namely ALT, AST, glucose, triglycerides and total cholesterol.
314 Thus, the effects on gene expression observed in treated mice with these doses were not associated
315 with significant hepatic cytolysis and systemic alterations of lipid homeostasis. Therefore, changes
316 in circadian gene expression observed for these doses might not be functionally significant. It would
317 be interesting to determine whether a much longer exposure to these low concentrations of
318 pharmaceuticals could have harmful effects on liver biology and integrity beyond the alterations of
319 gene expression. Furthermore, some selected circadian genes (e.g. Bmal1, Per1, Per2) could be
320 useful markers for further investigations specifically designed to look for potential genomic effects
321 of individual drug (or subset of drugs) included in the mixture.

322 It is now acknowledged that disturbances of circadian rhythmicity can promote different
323 metabolic disorders and chronic diseases such as dyslipidemia, insulin resistance, obesity and
324 cardiovascular diseases (Duez and Staels, 2008; Maury et al., 2010; Prasai et al., 2008). Moreover,
325 some studies showed that liver-specific deletion of genes involved in the liver clock could disturb
326 glucose and lipid homeostasis (Lamia et al., 2008; Tao et al., 2011). In this study, however, the
327 genomic response to drug exposure was investigated only in the liver. Hence, further investigations
328 would be required to determine whether an altered expression of clock genes could also be observed
329 in other tissues such as the CNS and in tissues playing a key role in carbohydrate and lipid
330 homeostasis. Different time points of the light-dark cycle should also be studied during these
331 investigations.

332 In this study, the 4-month treatment with the cocktail containing 10^6 ng/l of each drug
333 significantly increased plasma ALT and total cholesterol and changed the pattern of hepatic
334 steatosis in ob/ob mice, whereas these effects were not observed in wild-type mice. For this dosage,
335 the hepatic expression of most circadian genes in ob/ob mice was the highest, or the lowest, among
336 the different groups of animals. Interestingly, the daily intake corresponding to this dose (ca. 0.2
337 mg/kg/d) was well below the pharmacological dosages for all drugs included in the mixture. Indeed,
338 the daily dosage of these drugs is comprised between a few mg/kg/d for diclofenac and
339 roxithromycin to 40 and 60 mg/kg/d for salicylic acid and APAP, respectively. Importantly, some of
340 these drugs such as APAP, diclofenac, ibuprofen and salicylate can be taken over the long-term (i.e.
341 several months) for the treatment of inflammatory diseases or chronic pain (Kuffner et al., 2006;
342 Schaffer et al., 2006), which are often observed in obese patients (Guh et al. 2009; Wright et al.
343 2010). Thus, our work could also be relevant for obese patients with multiple drug prescriptions,
344 since obesity appears to increase the risk of hepatotoxicity, at least for some drugs (Fromenty, 2013;
345 Massart et al., 2012). Further investigations will be needed to determine whether the genomics

346 changes observed in this study could be involved in higher plasma ALT and total cholesterol
347 observed in ob/ob mice.

348 In conclusion, our study showed for the first time that chronic exposure to trace
349 pharmaceuticals was able to disturb the hepatic expression of genes involved in circadian rhythm in
350 lean and obese mice. This effect was dose-dependent and the expression of some circadian genes
351 was already dysregulated when the drinking water contained the 11 drugs at concentrations as low
352 as 10^2 and 10^3 ng/l. Moreover, drug mixture and obesity presented an additive effect on this gene
353 expression. Because some of the 11 drugs can be found in the drinking water at such concentrations
354 (e.g. APAP, caffeine, carbamazepine, ibuprofen, phenazone) further investigations would be needed
355 to determine whether our data could be extrapolated to human populations exposed to
356 pharmaceutical contaminants, in particular in countries with high prevalence of obesity.

357

358

359

360

361 **Acknowledgments**

362

363 This work was supported by a grant from the Agence Nationale de la Recherche (ANR contract
364 PHARMECO 09-CESA-014-01).

365

366

367 **Supplementary data**

368

369 Supplemental data were provided with this manuscript. The transcriptomic dataset (GSE49195)
370 presented in this study is available in the GEO database at the following URL address:
371 <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=jvqblqimewcyaju&acc=GSE49195>.

372

373

374

375 **Conflict of interest**

376

377 Sébastien Anthérieu, Dounia Menouer, Cédric Coulouarn, Karima Begriche, Viviane Trak-
378 Smayra, Sophie Martinais and Marie-Anne Robin have nothing to disclose. Mathieu Porceddu
379 reports co-founding of Mitologics SAS, outside the submitted work. Bernard Fromenty reports

380 personal fees from Medicines for Malaria Venture and from Medicen Paris Region, and a grant from
381 Société Francophone du Diabète, outside the submitted work.

382

383

384

385

386

387

388

389 **References**

390

391 Ando, H., Kumazaki, M., Motosugi, Y., Ushijima, K., Maekawa, T., Ishikawa, E., Fujimura,
392 A., 2011. Impairment of peripheral circadian clocks precedes metabolic abnormalities in ob/ob
393 mice. *Endocrinology* 152, 1347-1354.

394 Aubert, J., Begriche, K., Delannoy, M., Morel, I., Pajaud, J., Ribault, C., Lepage, S., McGill, M.R.,
395 Lucas-Clerc, C., Turlin, B., Robin, M.A., Jaeschke, H., Fromenty, B., 2012. Differences in early
396 acetaminophen hepatotoxicity between obese ob/ob and db/db mice. *J. Pharmacol. Exp. Ther.*
397 342, 676-687.

398 Begriche, K., Massart, J., Abbey-Toby, A., Igoudjil, A., Lettron, P., Fromenty, B., 2008. β -
399 Aminoisobutyric acid prevents diet-induced obesity in mice with partial leptin deficiency.
400 *Obesity* 16: 2053-2067.

401 Christiansen, S., Scholze, M., Dalgaard, M., Vinggaard, A.M., Axelstad, M., Kortenkamp, A., Hass
402 U., 2009. Synergistic disruption of external male sex organ development by a mixture of four
403 antiandrogens. *Environ. Health Perspect.* 117, 1839-1846.

404 Coulouarn, C., Corlu, A., Glaise, D., Gunon, I., Thorgeirsson, S.S., Clment, B., 2012. Hepatocyte-
405 stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that
406 drives progression in hepatocellular carcinoma. *Cancer Res.* 72, 2533-2542.

407 Daughton, C.G., Ternes, T.A., 1999. Pharmaceuticals and personal care products in the
408 environment: agents of subtle change? *Environ. Health Perspect.* 107(Suppl 6), 907-938.

409 Duez, H., Staels, B., 2008. Rev-erb alpha gives a time cue to metabolism. *FEBS Lett.* 582, 19-25.

410 Fromenty, B., 2013. Drug-induced liver injury in obesity. *J. Hepatol.* 58, 824-826.

411 Fromenty, B., Vadrot, N., Massart, J., Turlin, B., Barri-Ova, N., Lettron, P., Fautrel, A., Robin,
412 M.A., 2009. Chronic ethanol consumption lessens the gain of body weight, liver triglycerides,
413 and diabetes in obese ob/ob mice. *J. Pharmacol. Exp. Ther.* 331, 23-34.

414 Guh, D.P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C.L., Anis, A.H., 2009. The
415 incidence of co-morbidities related to obesity and overweight: a systematic review and meta-
416 analysis. *BMC Public Health* 9, 88.

417 Halling-Sorensen, B., Nielsen, S.N., Lanzky, P.F., Ingerslev, F., Holten Ltzhoft, H.C., Jorgensen,
418 S.E., 1998. Occurrence, fate and effects of pharmaceutical substances in the environment: a
419 review. *Chemosphere* 36, 357-393.

420 Heberer, T., 2002. Occurrence, fate and removal of pharmaceuticals residues in the aquatic
421 environment: a review of recent research data. *Toxicol. Lett.* 131, 5-17.

422 Kasprzyk-Hordern, B., Dinsdale, R.M., Guwy, A.J., 2008. The occurrence of pharmaceuticals,
 423 personal care products, endocrine disruptors and illicit drugs in surface water in South Wales,
 424 UK. *Water Res.* 42, 3498-3518.

425 Kortenkamp, A., Faust, M., Scholze, M., Backhaus, T., 2007. Low-level exposure to multiple
 426 chemicals: reason for human health concerns? *Environ. Health Perspect.* 115 (Suppl 1), 106-114.

427 Koyanagi, S., Okazawa, S., Kuramoto, Y., Ushijima, K., Shimeno, H., Soeda, S., Okamura, H.,
 428 Ohdo, S., 2006. Chronic treatment with prednisolone represses the circadian oscillation of clock
 429 gene expression in mouse peripheral tissues. *Mol. Endocrinol.* 20, 573-583.

430 Kuffner, E.K., Temple, A.R., Cooper, K.M., Baggish, J.S., Parenti, D.L., 2006. Retrospective
 431 analysis of transient elevations in alanine aminotransferase during long-term treatment with
 432 acetaminophen in osteoarthritis clinical trials. *Curr. Med. Res. Opin.* 22, 2137-2148.

433 Lamia, K.A., Storch, K.F., Weitz, C.J., 2008. Physiological significance of a peripheral tissue
 434 circadian clock. *Proc. Natl. Acad. Sci. USA* 105, 15172-15177.

435 Leung, L., Kalgutkar, A.S., Obach, R.S., 2012. Metabolic activation in drug-induced liver injury.
 436 *Drug Metab. Rev.* 44, 18-33.

437 Lindström, P., 2007. The physiology of obese-hyperglycemic mice [ob/ob mice].
 438 *ScientificWordJournal* 7, 666-685.

439 Massart, J., Robin, M.A., Noury, F., Fautrel, A., Lettéron, P., Bado, A., Eliat, P.A., Fromenty, B.,
 440 2012. Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing
 441 intestinal glucose absorption and activating hepatic lipogenesis. *Br. J. Pharmacol.* 165, 1361-
 442 1374.

443 Maury, E., Ramsey, K.M., Bass, J., 2010. Circadian rhythms and metabolic syndrome: from
 444 experimental genetics to human disease. *Circ. Res.* 106, 447-462.

445 Mompelat, S., Le Bot, B., Thomas, O., 2009. Occurrence and fate of pharmaceutical products and
 446 by-products, from resource to drinking water. *Environ. Int.* 35, 803-814.

447 Oike, H., Kobori, M., Suzuki, T., Ishida, N., 2011. Caffeine lengthens circadian rhythms in mice.
 448 *Biochem. Biophys. Res. Commun.* 410, 654-658.

449 Prasai, M.J., George, J.T., Scott, E.M., 2008. Molecular clocks, type 2 diabetes and cardiovascular
 450 disease. *Diab. Vasc. Dis. Res.* 5, 89-95.

451 Sanderson, H., 2011. Presence and risk assessment of pharmaceuticals in surface water and drinking
 452 water. *Water Sci. Technol.* 63, 2143-2148.

453 Schaffer, D., Florin, T., Eagle, C., Marschner, I., Singh, G., Grobler, M., Fenn, C., Schou, M.,
 454 Curnow, K.M., 2006. Risk of serious NSAID-related gastrointestinal events during long-term
 455 exposure: a systematic review. *Med. J. Aust.* 185, 501-506.

456 Sharma, A., Bartell, S.M., Baile, C.A., Chen, B., Podolsky, R.H., McIndoe, R.A., She, J.X., 2010.
 457 Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss
 458 in ob/ob mice. *PLoS One* 5, e12147.

459 Sherman, H., Gutman, R., Chapnik, N., Meylan, J., le Coutre, J., Froy, O., 2011. Caffeine alters
 460 circadian rhythms and expression of disease and metabolic markers. *Int. J. Biochem. Cell. Biol.*
 461 43, 829-838.

462 Shinohara, A., Koyanagi, S., Hamdan, A.M., Matsunaga, N., Aramaki, H., Ohdo, S., 2008. Dosing
 463 schedule-dependent change in the disruptive effects of interferon- α on the circadian clock
 464 function. *Life Sci.* 83, 574-580.

465 Stackelberg, P.E., Furlong, E., Meyer, M.T., Zaugg, S.D., Henderson, A.K., Reissman, D.B., 2004.
 466 Persistence of pharmaceutical compounds and other organic wastewater contaminants in a
 467 conventional drinking-water treatment plant. *Sci. Total Environ.* 329, 99-113.

468 Sulpice, L., Rayar, M., Desille, M., Turlin, B., Fautrel, A., Boucher, E., Llamas-Gutierrez, F.,
 469 Meunier, B., Boudjema, K., Clément, B., Coulouarn, C., 2013. Molecular profiling of stroma
 470 identifies osteopontin as an independent predictor of poor prognosis in intrahepatic
 471 cholangiocarcinoma. *Hepatology* 58, 1992-2000.

472 Tao, W., Chen, S., Shi, G., Guo, J., Xu, Y., Liu, C., 2011. SWItch/sucrose nonfermentable
 473 (SWI/SNF) complex subunit BAF60a integrates hepatic circadian clock and energy metabolism.
 474 *Hepatology* 54, 1410-1420.

475 Terazono, H., Hamdan, A., Matsunaga, N., Hayasaka, N., Kaji, H., Egawa, T., Makino, K.,
 476 Shigeyoshi, Y., Koyanagi, S., Ohdo, S., 2008. Modulatory effects of 5-fluorouracil on the
 477 rhythmic expression of circadian clock genes: a possible mechanism of chemotherapy-induced
 478 circadian rhythm disturbances. *Biochem. Pharmacol.* 75, 1616-1622.

479 Trak-Smayra, V., Paradis, V., Massart, J., Nasser, S., Jebara, V., Fromenty, B., 2011. Pathology of
 480 the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. *Int. J.*
 481 *Exp. Pathol.* 92, 413-21.

482 Webb, S., Ternes, T., Gibert, M., Olejniczak, K., 2003. Indirect human exposure to pharmaceuticals
 483 via drinking water. *Toxicol. Lett.* 142, 157-167.

484 Wright, L.J., Schur, E., Noonan, C., Ahumada, S., Buchwald, D., Afari, N., 2010. Chronic pain,
 485 overweight, and obesity: findings from a community-based twin registry. *J. Pain* 11, 628-635.

486 Xu, Y.Q., Zhang, D., Jin, T., Cai, D.J., Wu, Q., Lu, Y., Liu, J., Klaassen, C.D., 2012. Diurnal
 487 variation of hepatic antioxidant gene expression in mice. *PLoS One* 7, e44237.

488 Yang, J.S., Kim, J.T., Jeon, J., Park, H.S., Kang, G.H., Park, K.S., Lee, H.K., Kim, S., Cho, Y.M.,
 489 2010. Changes in hepatic gene expression upon oral administration of taurine-conjugated
 490 ursodeoxycholic acid in ob/ob mice. *PLoS One* 5, e13858.

491 Ye, Z., Weinberg, H.S., 2007. Trace analysis of trimethoprim and sulfonamide, macrolide,
492 quinolone, and tetracycline antibiotics in chlorinated drinking water using liquid chromatography
493 electrospray tandem mass spectrometry. *Anal. Chem.* 79, 1135-1144.

494 Yu, Z., Peldszus, S., Huck, P.M., 2007. Optimizing gas chromatographic-mass spectrometric
495 analysis of selected pharmaceuticals and endocrine-disrupting substances in water using
496 factorial experimental design. *J. Chromatogr. A* 1148, 65-77.

497 Zuccato, E., Calamari, D., Natangelo, M., Fanelli, R., 2000. Presence of therapeutic drugs in the
498 environment. *Lancet* 355, 1789-1790.

499

500 **Table 1.**

501 Body weight gain and plasma parameters in the different groups of mice at the end of the treatment.

Animals	Treatment	Body weight gain (g)	Glucose (mM)	Total cholesterol (mM)	Triglycerides (mM)	ALAT (UI/L)	ASAT (UI/L)
Lean	0	11.1 ± 0.8	9.6 ± 0.9	2.49 ± 0.12	1.42 ± 0.17	86 ± 15	194 ± 50
	10 ng/l	9.8 ± 2.1	9.2 ± 0.6	2.21 ± 0.09	1.00 ± 0.09	90 ± 13	147 ± 25
	10 ² ng/l	11.4 ± 0.7	8.8 ± 0.4	2.28 ± 0.08	1.21 ± 0.16	76 ± 9	164 ± 30
	10 ³ ng/l	10.5 ± 0.4	9.4 ± 0.4	2.31 ± 0.09	1.15 ± 0.08	113 ± 26	187 ± 24
	10 ⁴ ng/l	11.9 ± 0.5	10.0 ± 0.4	2.43 ± 0.05	1.29 ± 0.10	71 ± 5	145 ± 23
	10 ⁵ ng/l	12.8 ± 0.3	10.2 ± 0.6	2.67 ± 0.08	1.34 ± 0.03	147 ± 27	189 ± 14
	10 ⁶ ng/l	11.3 ± 0.6	9.9 ± 0.5	2.53 ± 0.09	1.35 ± 0.18	101 ± 13	159 ± 24
ob/ob	0	30.4 ± 0.8	7.2 ± 0.7	7.88 ± 0.38	1.27 ± 0.12	708 ± 50	451 ± 24
	10 ng/l	27.7 ± 1.5	10.2 ± 3.1	7.43 ± 0.65	1.12 ± 0.09	672 ± 62	674 ± 105
	10 ² ng/l	31.7 ± 1.6	8.1 ± 0.9	7.81 ± 0.29	1.06 ± 0.02	674 ± 75	587 ± 85
	10 ³ ng/l	30.0 ± 0.6	9.5 ± 1.2	7.73 ± 0.44	1.16 ± 0.08	533 ± 58†	372 ± 42
	10 ⁴ ng/l	31.3 ± 0.9	8.9 ± 0.7	8.16 ± 0.32	1.19 ± 0.08	683 ± 43	748 ± 230
	10 ⁵ ng/l	33.3 ± 0.5	9.8 ± 1.0	8.46 ± 0.29	1.07 ± 0.03	844 ± 104	759 ± 133
	10 ⁶ ng/l	29.1 ± 0.9	9.4 ± 0.5	8.83 ± 0.28†	1.29 ± 0.05	936 ± 56†	702 ± 76
Two-way ANOVA analysis		G,T		G,T		G,T,GxT	G

502 Note: Plasma parameters were determined in the fed state. Body weight gain was calculated for each mouse over
503 the 4 months of treatment. Results are mean ± SEM for 5 to 7 mice. Statistical analysis was performed with a two-
504 way ANOVA: G, effect of genotype, T, effect of treatment, GxT, interaction between genotype and treatment.
505 Individual means were then compared with the *post hoc* Bonferroni test. †Significantly different from untreated
506 mice of the same genotype (*P*<0.05).

507

508 Table 2.

509 Top 10 well-annotated genes that were up or down-regulated in liver of wild-type and ob/ob mice treated with
510 the cocktail containing 10^6 ng/l of each drug.

Up-regulated in both lean and ob/ob mice ^a	Name (Accession number)	Gene ontology ^b
Dbp (lean 3.70 ; ob 2.08) ^c	D site albumin promoter binding protein (NM_016974)	Circadian rhythm. Positive regulation of transcription from RNA polymerase II promoter
Alas1 (lean 2.56 ; ob 1.52)	Aminolevulinic acid synthase 1 (NM_020559)	Biosynthetic process. Heme biosynthetic process
Ypel1 (lean 1.89 ; ob 1.54)	Yippee-like 1 (Drosophila) (NM_023249)	Negative regulation of protein kinase B signaling cascade. Regulation of myelination
Gnat1 (lean 1.79 ; ob 1.79)	Guanine nucleotide binding protein, alpha transducing 1 (NM_008140)	Adenylate cyclase-modulating G-protein coupled receptor signaling pathway. Cell proliferation
Pfkfb3 (lean 1.79 ; ob 1.59)	6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (NM_133232)	Fructose 2,6-biphosphate metabolic process. Phosphorylation
Arrdc3 (lean 1.79 ; ob 1.52)	Arrestin domain containing 3 (NM_001042591)	Fat pad development. Negative regulation of heat generation
Down-regulated in both lean and ob/ob mice	Name (Accession number)	Gene ontology
Cry1 (lean 0.38 ; ob 0.65)	Cryptochrome 1 (photolyase-like) (NM_007771)	Circadian rhythm. DNA repair
Hmgcs1 (lean 0.45 ; ob 0.61)	3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (AK078743)	Cholesterol biosynthetic process. Isoprenoid biosynthetic process
Trim27 (lean 0.45 ; ob 0.63)	Tripartite motif-containing 27 (AK049314)	Interferon gamma secretion. Negative regulation of adaptive immune response
Cstad (lean 0.50 ; ob 0.63)	CSA-conditional, T cell activation-dependent protein (NM_030137)	Mitochondrial membrane organization
Avpr1a (lean 0.54 ; ob 0.67)	Arginine vasopressin receptor 1A (NM_016847)	Calcium-mediated signaling. Elevation of cytosolic calcium ion concentration
Lonrf3 (lean 0.56 ; ob 0.58)	LON peptidase N-terminal domain and ring finger 3 (NM_028894)	Proteolysis
Cdca2 (lean 0.56 ; ob 0.61)	Cell division cycle associated 2 (NM_175384)	Cell cycle. Cell division
Arntl (lean 0.57 ; ob 0.36)	Aryl hydrocarbon receptor nuclear translocator-like (NM_007489)	Circadian regulation of gene expression. Circadian rhythm
Chka (lean 0.60 ; ob 0.56)	Choline kinase alpha (NM_013490)	CDP-choline pathway. Glycerophospholipid biosynthetic process
Cxadr (lean 0.62 ; ob 0.56)	Coxsackie virus and adenovirus receptor (NM_009988)	Actin cytoskeleton reorganization. AV node cell to bundle of His cell communication
Up-regulated only in lean mice	Name	Gene ontology
Cfd (4.35)	Complement factor D (adipsin) (NM_013459)	Complement activation, alternative pathway. Innate immune response
H19 (3.85)	H19 fetal liver mRNA (AK003142)	Negative regulation of cell proliferation. Regulation of gene expression
Tppp3 (2.94)	Tubulin polymerization-promoting protein family member 3 (NM_026481)	Microtubule bundle formation
Inhbb (2.63)	Inhibin beta-B (NM_008381)	Activin receptor signaling pathway. Cellular response to cholesterol
Kif23 (2.50)	Kinesin family member 23 (NM_024245)	Spindle midzone assembly involved in mitosis
E2f7 (2.44)	E2F transcription factor 7 (NM_178609)	Cell cycle. Chorionic trophoblast cell differentiation
Pdlim3 (2.44)	PDZ and LIM domain 3 (NM_016798)	Actin filament organization. Heart development
Igfbp6 (2.38)	Insulin-like growth factor binding protein 6 (X81584)	Regulation of cell growth
Esm1 (2.33)	Endothelial cell-specific molecule 1 (NM_023612)	Biological process. Regulation of cell growth
Il1rap (2.33)	Interleukin 1 receptor accessory protein (NM_008364)	Cytokine-mediated signaling pathway. Innate immune response
Down-regulated only in lean mice	Name	Gene ontology
Fos (0.19) ²	FBJ osteosarcoma oncogene (NM_010234)	Cellular response to cellular calcium ion. Cellular response to extracellular stimulus.
Nr4a1 (0.21)	Nuclear receptor subfamily 4, group A, member 1 (NM_010444)	Apoptotic process. Cell migration involved in sprouting angiogenesis
Egr1 (0.31)	Early growth response 1 (NM_007913)	Bone morphogenetic protein signaling pathway. Cellular

		response to gamma radiation
Dusp1 (0.36)	Dual specificity phosphatase 1 (NM_013642)	Cell cycle. Dephosphorylation
Igh-VJ558 (0.40)	Immunoglobulin heavy chain (J558 family) (XM_001474025)	
Igfbp1 (0.40)	Insulin-like growth factor binding protein 1 (NM_008341)	Regulation of cell growth
Fam65b (0.42)	Family with sequence similarity 65, member B (NM_029679)	Biological process
Zfp36 (0.44)	Zinc finger protein 36 (NM_011756)	3'-UTR-mediated mRNA stabilization. Intracellular protein kinase cascade
Fam110c (0.45)	Family with sequence similarity 110, member C (NM_027828)	Positive regulation of cell migration. Positive regulation of protein kinase B signaling cascade
Slc34a2 (0.46)	Solute carrier family 34 (sodium phosphate), member 2 (NM_011402)	Cellular phosphate ion homeostasis. In utero embryonic development
Up-regulated only in ob/ob mice	Name	Gene ontology
Clec2d (2.86)	C-type lectin domain family 2, member d (NM_053109)	Cellular defense response. Negative regulation of osteoclast differentiation
Usp2 (2.78)	Ubiquitin specific peptidase (NM_198092)	Cell cycle. Muscle organ development
Mt2 (2.63)	Metallothionein 2 (NM_008630)	Cellular response to drug. Cellular zinc ion homeostasis
Upp2 (2.56)	Uridine phosphorylase 2 (NM_029692)	Metabolic process. Nucleoside metabolic process
Mt1 (2.44)	Metallothionein 1 (NM_013602)	Cellular metal ion homeostasis. Cellular response to chromate
Krt20 (2.33)	Keratin 20 (NM_023256)	Apoptotic process. Cellular response to stress
Rgs16 (2.27)	Regulator of G-protein signaling 16 (NM_011267)	G-Protein coupled receptor signaling pathway. Negative regulation of signal transduction
Car3 (2.08)	Carbonic anhydrase 3 (AK075630)	One-carbon metabolic process. Response to oxidative stress
Grm8 (1.92)	Glutamate receptor, metabotropic 8 (NM_008174)	Adenylate cyclase inhibiting G-protein coupled glutamate receptor signaling pathway. G-protein coupled receptor signaling pathway
Cdc6 (1.85)	Cell division cycle 6 homolog (S. cerevisiae) (NM_011799)	Cell cycle. Cell division
Down-regulated only in ob/ob mice	Name	Gene ontology
Moxd1 (0.18)	Monooxygenase, DBH-like 1 (NM_021509)	Catecholamine metabolic process. Oxidation-reduction process
Hsd3b5 (0.18)	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5 (NM_008295)	Oxidation-reduction process. Steroid biosynthetic process
Man2a2 (0.40)	Mannosidase 2, alpha 2 (NM_172903)	Carbohydrate metabolic process. Mannose metabolic process
Usp26 (0.45)	Ubiquitin specific peptidase 26 (NM_031388)	Protein deubiquitination. Proteolysis
Gadd45g (0.45)	Growth arrest and DNA-damage-inducible 45 gamma (NM_011817)	Activation of MAPKK activity. Apoptotic process
Atp2b2 (0.45)	ATPase, Ca ²⁺ transporting, plasma membrane 2 (NM_009723)	ATP catabolic process. Calcium ion export
Ppp1r9a (0.46)	Protein phosphatase 1, regulatory (inhibitor) (NM_181595)	Actin filament organization. Calcium-mediated signaling
Kalrn (0.47)	Kalirin, RhoGEF kinase (AK051053)	Axonogenesis. Intracellular signal transduction
Murc (0.48)	Muscle-related coiled-coil protein (NM_026509)	Cardiac myofibril assembly. Cell differentiation
Elovl3 (0.48)	Elongation of very long chain fatty acids-like 3 (NM_007703)	Fatty acid biosynthetic process. Fatty acid elongation, monounsaturated fatty acid

511 Note:^aLess than 10 genes were found to be modulated by the drug mixture in this category. ^bThe first 2 terms were selected by
512 using the Amigo Gene Ontology website, with “*Mus musculus*” and “*Biological process*” as filters. ^cThe number in parentheses
513 is the fold change given by the microarray analysis.

514

515

516

517

518
519
520
521

Legends to the figures

522
523
524
525
526

Figure 1. Hepatic steatosis in obese ob/ob mice treated or not with the cocktail containing 10^6 ng/l of each drug. Liver sections were stained with H&E and pictures were taken at 200x magnification. Mice presented in panels A, B and C are those numbered 1, 14 and 18 in Supplementary Table 1.

528

529 **Figure 2.** Hepatic mRNA expression of 8 circadian genes in male lean and obese mice treated or not
530 with the cocktail containing the 11 drugs at concentrations ranging from 10 to 10⁶ ng/l. Results are
531 mean ± SEM for 5 to 7 mice. Statistical analysis was performed with a two-way ANOVA: G, effect
532 of genotype, T, effect of treatment, GxT, interaction between genotype and treatment. Individual
533 means were then compared with the *post hoc* Bonferroni test. †Significantly different from
534 untreated mice of the same genotype ($P<0.05$).

536 **Figure 3.** Hepatic mRNA expression of 8 circadian genes in female lean and obese mice treated or
537 not with the cocktail containing the 11 drugs at concentrations ranging from 10^4 to 10^6 ng/l. Results
538 are mean $\pm$ SEM for 4 to 8 mice. Statistical analysis was performed with a two-way ANOVA: G,
539 effect of genotype, T, effect of treatment, GxT, interaction between genotype and treatment.
540 Individual means were then compared with the *post hoc* Bonferroni test. †Significantly different
541 from untreated mice of the same genotype ($P<0.05$).
542
543

Figure 4. Hepatic mRNA expression of 6 non-circadian genes in male lean and obese mice treated or not with the cocktail containing the 11 drugs at concentrations ranging from 10 to 10^6 ng/l. Results are mean $\pm$ SEM for 5 to 7 mice. Statistical analysis was performed with a two-way ANOVA: G, effect of genotype, T, effect of treatment, GxT, interaction between genotype and treatment. Individual means were then compared with the *post hoc* Bonferroni test. †Significantly different from untreated mice of the same genotype ($P < 0.05$).